The CD4+, CD8+ and tetramer+CD8+ T cell populations in splenocytes in FeMOF-based cancer vaccines in large size (OVA-ML) and small size (OVA-MS) are significantly higher than saline group and free OVA group. This evidence concerns the gene CD8A and cancer.